/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

BOLT BIOTHERAPEUTICS INC Share Price Today: Live Updates & Key Insights

BOLT BIOTHERAPEUTICS INC share price today is $4.1928, up -1.94%. The stock opened at $4.0643 against the previous close of $4.13, with an intraday high of $4.1 and low of $4.0643.

BOLT BIOTHERAPEUTICS INC Share Price Chart

style
pb-0

BOLT BIOTHERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

BOLT BIOTHERAPEUTICS INC Share Price Performance

$4.1928 -0.0194(-1.94%) BOLT at 13 Mar 2026 12:16 PM Biotechnology
Lowest Today 4.0643
Highest Today 4.1
Today’s Open 4.0643
Prev. Close 4.13
52 Week High 9.66
52 Week Low 4.01
Day’s Range: Low 4.0643 High 4.1
52-Week Range: Low 4.01 High 9.66
1 day return -
1 Week return +4.61
1 month return -14.82
3 month return -20.03
6 month return -25.17
1 year return +977.5
3 year return +207.85
5 year return -88.88
10 year return -

BOLT BIOTHERAPEUTICS INC Institutional Holdings

Sofinnova Ventures 7.18

Pivotal bioVenture Partners Investment Advisor LLC 4.93

Vivo Capital, LLC 3.77

TANG CAPITAL MANAGEMENT LLC 3.48

Nan Fung Group Holdings Ltd 3.04

Renaissance Technologies Corp 2.87

Board of Ttees Leland Stanford Jr Univ 1.87

Pfizer Inc 1.63

NANO CAP NEW MILLENNIUM GROWTH FUND L P 1.07

Geode Capital Management, LLC 0.97

Susquehanna International Group, LLP 0.87

Shay Capital LLC 0.80

DRW Securities, LLC 0.64

Vanguard Group Inc 0.53

BlackRock Inc 0.51

Fidelity Extended Market Index 0.37

Vanguard Institutional Extnd Mkt Idx Tr 0.37

PGIM US Micro Cap Quant Equity 0.30

Fidelity Total Market Index 0.28

NT Ext Equity Mkt Idx Fd - L 0.26

Spartan Extended Market Index Pool F 0.16

Morgan Stanley - Brokerage Accounts 0.16

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.10

Fidelity Series Total Market Index 0.09

Blackrock Extended Mkt Fund CF 0.08

Northern Trust Extended Eq Market Idx 0.07

Spartan Total Market Index Pool G 0.07

Extended Equity Market Fund K 0.07

NT Ext Equity Mkt Idx Fd - NL 0.04

Vanguard Instl Ttl Stck Mkt Idx Tr 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

Tower Research Capital LLC 0.01

State St US Extended Mkt Indx NL Cl C 0.01

BNYM Mellon SL Market Completion UC1 0.01

Fidelity Nasdaq Composite Index 0.01

Extended Equity Market Fund M 0.01

SSgA U.S. Total Market Index Strategy 0.01

JPMorgan Chase & Co 0.00

Bank of America Corp 0.00

SBI Securities Co Ltd 0.00

BOLT BIOTHERAPEUTICS INC Market Status

Strong Buy: 1

Buy: 0

Hold: 3

Sell: 0

Strong Sell: 0

BOLT BIOTHERAPEUTICS INC Fundamentals

Market Cap 7.93 M

PB Ratio 0.2469

PE Ratio 0.0

Enterprise Value -0.39 M

Total Assets 99.63 M

Volume 6827

BOLT BIOTHERAPEUTICS INC Company Financials

Annual Revenue FY23:7198000 7.2M, FY22:5729000 5.7M, FY21:1260000 1.3M, FY20:231000 0.2M, FY19:215000 0.2M

Annual Profit FY23:null 0.0M, FY22:5729000 5.7M, FY21:1260000 1.3M, FY20:231000 0.2M, FY19:215000 0.2M

Annual Net worth FY23:-71291000 -71.3M, FY22:-85875000 -85.9M, FY21:-104394000 -104.4M, FY20:-72274000 -72.3M, FY19:-30005000 -30.0M

Quarterly Revenue Q3/2025:2169000 2.2M, Q2/2025:1804000 1.8M, Q1/2025:1222000 1.2M, Q3/2024:1141000 1.1M, Q2/2024:1275000 1.3M

Quarterly Profit Q3/2025:1879000 1.9M, Q2/2025:1804000 1.8M, Q1/2025:1222000 1.2M, Q3/2024:1141000 1.1M, Q2/2024:-14158000 -14.2M

Quarterly Net worth Q3/2025:-7144000 -7.1M, Q2/2025:-8561000 -8.6M, Q1/2025:-11040000 -11.0M, Q3/2024:-15176000 -15.2M, Q2/2024:-21195000 -21.2M

About BOLT BIOTHERAPEUTICS INC & investment objective

Company Information Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Organisation Biotechnology

Employees 40

Industry Biotechnology

CEO Mr. William P. Quinn

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow